MX2014012527A - Dihidrato de un compuesto de benzotiofeno o de una sal del mismo y proceso para producir el mismo. - Google Patents

Dihidrato de un compuesto de benzotiofeno o de una sal del mismo y proceso para producir el mismo.

Info

Publication number
MX2014012527A
MX2014012527A MX2014012527A MX2014012527A MX2014012527A MX 2014012527 A MX2014012527 A MX 2014012527A MX 2014012527 A MX2014012527 A MX 2014012527A MX 2014012527 A MX2014012527 A MX 2014012527A MX 2014012527 A MX2014012527 A MX 2014012527A
Authority
MX
Mexico
Prior art keywords
dihydrate
salt
producing
same
benzothiophene compound
Prior art date
Application number
MX2014012527A
Other languages
English (en)
Other versions
MX361723B (es
Inventor
Hiroshi Yamashita
Takuya Minowa
Tetsuya Sato
Yusuke Hoshika
Hidekazu Toyofuku
Tatsuya Yamaguchi
Masahiro Sota
Shuuji Kawano
Takayuki Nakamura
Ryohei Eto
Takuma Ikebuchi
Kei Moriyama
Nobuaki Ito
Original Assignee
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48428584&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2014012527(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd
Publication of MX2014012527A publication Critical patent/MX2014012527A/es
Publication of MX361723B publication Critical patent/MX361723B/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Otolaryngology (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

La presente invención se refiere a proporcionar un compuesto que puede usarse como un agente terapéutico superior para las enfermedades del sistema nervioso central. La presente invención proporciona un dihidrato de 7-[4- (4-benzo[b]tiofen-4-il-piperazin -1-il)butoxi] -1H-quinolin-2-ona o de una sal del mismo y un proceso para producir el mismo.
MX2014012527A 2012-04-23 2013-04-23 Dihidrato de un compuesto de benzotiofeno o de una sal del mismo y proceso para producir el mismo. MX361723B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261636920P 2012-04-23 2012-04-23
US201361791378P 2013-03-15 2013-03-15
PCT/JP2013/062681 WO2013162046A1 (en) 2012-04-23 2013-04-23 Dihydrate of benzothiophene compound or of a salt thereof, and process for producing the same

Publications (2)

Publication Number Publication Date
MX2014012527A true MX2014012527A (es) 2015-03-19
MX361723B MX361723B (es) 2018-12-14

Family

ID=48428584

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014012527A MX361723B (es) 2012-04-23 2013-04-23 Dihidrato de un compuesto de benzotiofeno o de una sal del mismo y proceso para producir el mismo.

Country Status (37)

Country Link
US (5) US9499525B2 (es)
EP (1) EP2841431B2 (es)
JP (1) JP5952917B2 (es)
KR (1) KR102160395B1 (es)
CN (1) CN104254530B (es)
AR (1) AR090774A1 (es)
AU (1) AU2013253372B2 (es)
BR (1) BR112014026424B1 (es)
CA (1) CA2870000C (es)
CO (1) CO7111315A2 (es)
CY (1) CY1119103T1 (es)
DK (1) DK2841431T4 (es)
EA (1) EA026541B1 (es)
ES (1) ES2617881T5 (es)
FI (1) FI2841431T4 (es)
HK (1) HK1203073A1 (es)
HR (1) HRP20170242T4 (es)
HU (1) HUE031997T2 (es)
IL (1) IL235044B (es)
IN (1) IN2014DN08867A (es)
JO (1) JO3325B1 (es)
LT (1) LT2841431T (es)
ME (1) ME02619B (es)
MX (1) MX361723B (es)
MY (1) MY170220A (es)
NZ (1) NZ630260A (es)
PH (1) PH12014502324A1 (es)
PL (1) PL2841431T3 (es)
PT (1) PT2841431T (es)
RS (1) RS55742B2 (es)
SG (1) SG11201406790VA (es)
SI (1) SI2841431T2 (es)
SM (1) SMT201700130B (es)
TW (1) TWI562991B (es)
UA (1) UA117456C2 (es)
WO (1) WO2013162046A1 (es)
ZA (1) ZA201407477B (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI320783B (en) * 2005-04-14 2010-02-21 Otsuka Pharma Co Ltd Heterocyclic compound
AR090775A1 (es) * 2012-04-23 2014-12-03 Otsuka Pharma Co Ltd Preparado inyectable
TWI562991B (en) * 2012-04-23 2016-12-21 Otsuka Pharma Co Ltd Dihydrate of benzothiophene compound or of a salt thereof, and process for producing the same
JOP20200109A1 (ar) 2012-04-23 2017-06-16 Otsuka Pharma Co Ltd مستحضر قابل للحقن
JOP20210047A1 (ar) * 2012-10-25 2017-06-16 Otsuka Pharma Co Ltd عامل وقائي و/أو علاجي للأعراض السلوكية والنفسية المصحوبة بمرض تنكسي عصبي أو الأعراض الإندفاعية المصحوبة بمرض ذهني، يحتوي على بريكسبيرازول أو ملحه
BR112016024510A2 (pt) 2014-04-22 2017-08-15 H Lundbeck As ?medicamento, uso de brexpiprazol ou de um sal farmaceuticamente aceitável do mesmo, métodos para prevenção ou tratamento de um transtorno relacionado com substância e para produção de uma composição farmacêutica, composição farmacêutica, e, kit?
CN104447723A (zh) * 2014-11-28 2015-03-25 瑞阳制药有限公司 7-(4-(4-(苯并[b]噻吩基)-1-哌嗪基)丁氧基)-2(1H)-喹啉酮的制备方法
CN104829603A (zh) * 2015-05-19 2015-08-12 杭州新博思生物医药有限公司 A晶型依匹唑派盐酸盐及其制备方法
CN106883223B (zh) * 2015-12-16 2021-11-23 北京福元医药股份有限公司 一种Brexpiprazole盐酸盐的纯化方法
WO2017106641A1 (en) 2015-12-17 2017-06-22 Assia Chemical Industries Ltd. Solid state forms of brexpiprazole
JP2019059672A (ja) * 2015-12-28 2019-04-18 大日本住友製薬株式会社 治療抵抗性うつ病等の治療薬
EP3397636B1 (en) 2015-12-28 2021-08-04 Honour (R&D) Process for the preparation of quinoline-2(1h)-one derivatives
US10501450B2 (en) 2016-02-01 2019-12-10 Hexal Ag Anhydrate-free polymorphically pure micronized crystalline brexpiprazole di-hydrate for use in intramuscular injectable sustained release formulations
US20170320862A1 (en) 2016-05-03 2017-11-09 Cadila Healthcare Limited Process for the preparation of brexpiprazole and intermediates thereof
CN107365305A (zh) * 2016-05-12 2017-11-21 上海奥博生物医药技术有限公司 一种依匹哌唑新晶型及其制备方法
WO2017208251A1 (en) * 2016-05-31 2017-12-07 Cipla Limited A new stable polymorph of brexpiprazole and process for preparation thereof
CN106188023A (zh) * 2016-07-04 2016-12-07 山东川成医药股份有限公司 一种依匹唑派的精制方法
PL233778B1 (pl) 2016-07-19 2019-11-29 Adamed Spolka Z Ograniczona Odpowiedzialnoscia Sposob wytwarzania brekspiprazolu oraz zastosowanie zwiazkow posrednich w sposobie wytwarzania brekspiprazolu
WO2018033481A1 (en) 2016-08-16 2018-02-22 H E X A L Aktiengesellschaft Immediate release tablet of a benzothiophene compound
US20200093821A1 (en) 2016-08-16 2020-03-26 Hexal Ag Pharmaceutical Compositions of a Benzothiophene Compound
CN107936005A (zh) * 2016-10-13 2018-04-20 上海科胜药物研发有限公司 一种依匹哌唑新晶型ii及其制备方法
CN111233848A (zh) * 2016-12-14 2020-06-05 上海博志研新药物技术有限公司 一种依匹哌唑甲醇合物、晶型a、及其制备方法和应用
EP3577111A1 (en) 2017-02-02 2019-12-11 Hexal Aktiengesellschaft Crystalline brexpiprazole
EP3501506B1 (en) 2017-12-19 2019-10-09 Alfred E. Tiefenbacher (GmbH & Co. KG) Pharmaceutical tablet composition comprising brexpiprazole
CN111440158A (zh) * 2020-03-24 2020-07-24 石药集团中奇制药技术(石家庄)有限公司 一种盐酸依匹哌唑新晶型及其制备方法
US11229644B1 (en) * 2020-12-31 2022-01-25 Lake O'hara Llc Methods of treating psychiatric disorders in obese patients with brexpiprazole
WO2022176017A1 (ja) * 2021-02-16 2022-08-25 大塚製薬株式会社 非晶質体及び当該非晶質体を含む組成物
WO2023067664A1 (ja) * 2021-10-18 2023-04-27 大塚製薬株式会社 ベンゾチオフェン化合物の新規結晶形及びその製造方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR033485A1 (es) * 2001-09-25 2003-12-26 Otsuka Pharma Co Ltd Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma
PL1675573T4 (pl) 2003-10-23 2016-04-29 Otsuka Pharma Co Ltd Sterylny preparat do wstrzykiwań arypiprazolu o kontrolowanym uwalnianiu i sposób
WO2006030446A1 (en) 2004-09-13 2006-03-23 Matrix Laboratories Ltd Process for the preparation of polymorphs, solvates of aripiprazole using aripiprazole acid salts
DE102005001989A1 (de) * 2005-01-15 2006-07-20 Bayer Healthcare Ag Intravenöse Formulierungen von PDE-Inhibitoren
JP4315393B2 (ja) 2005-04-14 2009-08-19 大塚製薬株式会社 複素環化合物
TWI320783B (en) * 2005-04-14 2010-02-21 Otsuka Pharma Co Ltd Heterocyclic compound
PE20090387A1 (es) * 2007-05-24 2009-04-28 Novartis Ag Formulacion de pasireotida
US20100285476A1 (en) * 2007-10-26 2010-11-11 Rusche James R Methods of identifying histone deacetylase inhibitors useful for neurological disorders
WO2009095450A1 (en) * 2008-01-30 2009-08-06 Novartis Ag Sustained release formulation comprising octreotide and three linear polylactide-co-glycolide polymers
RU2535089C2 (ru) 2010-08-24 2014-12-10 Оцука Фармасьютикал Ко., Лтд. Суспензия и затвердевшая композиция, содержащие производное карбостирила и силиконовое масло и/или производное силиконового масла
JP2012232958A (ja) * 2011-05-09 2012-11-29 Otsuka Pharmaceut Co Ltd 注射製剤
TWI546299B (zh) * 2011-07-28 2016-08-21 大塚製藥股份有限公司 用於製造苯并[b]噻吩之方法
JO3227B1 (ar) * 2011-09-08 2018-03-08 Otsuka Pharma Co Ltd مشتقات بنزو ثيوفين بها استبدال ببرازين كعوامل مضادة للذهان
JOP20200109A1 (ar) * 2012-04-23 2017-06-16 Otsuka Pharma Co Ltd مستحضر قابل للحقن
AR090775A1 (es) * 2012-04-23 2014-12-03 Otsuka Pharma Co Ltd Preparado inyectable
TWI562991B (en) * 2012-04-23 2016-12-21 Otsuka Pharma Co Ltd Dihydrate of benzothiophene compound or of a salt thereof, and process for producing the same

Also Published As

Publication number Publication date
PL2841431T3 (pl) 2017-06-30
HK1203073A1 (en) 2015-10-16
AR090774A1 (es) 2014-12-03
ES2617881T5 (es) 2024-05-22
UA117456C2 (uk) 2018-08-10
US10407415B2 (en) 2019-09-10
HRP20170242T4 (hr) 2024-03-01
RS55742B2 (sr) 2024-04-30
US20200140424A1 (en) 2020-05-07
EP2841431B1 (en) 2017-01-04
MY170220A (en) 2019-07-10
PH12014502324B1 (en) 2015-01-12
BR112014026424A2 (pt) 2017-06-27
JO3325B1 (ar) 2019-03-13
PT2841431T (pt) 2017-03-07
JP2015514677A (ja) 2015-05-21
FI2841431T4 (fi) 2024-04-18
RS55742B1 (sr) 2017-07-31
KR102160395B1 (ko) 2020-09-28
NZ630260A (en) 2015-09-25
HRP20170242T8 (hr) 2017-09-22
US9499525B2 (en) 2016-11-22
HRP20170242T1 (hr) 2017-04-07
CN104254530B (zh) 2016-09-21
CA2870000A1 (en) 2013-10-31
EA201491933A1 (ru) 2015-03-31
KR20150013189A (ko) 2015-02-04
CY1119103T1 (el) 2018-02-14
US20230049327A1 (en) 2023-02-16
MX361723B (es) 2018-12-14
CA2870000C (en) 2021-02-16
SI2841431T2 (sl) 2024-03-29
EP2841431A1 (en) 2015-03-04
EA026541B1 (ru) 2017-04-28
SG11201406790VA (en) 2014-11-27
ME02619B (me) 2017-06-20
CN104254530A (zh) 2014-12-31
HUE031997T2 (en) 2017-08-28
TWI562991B (en) 2016-12-21
SI2841431T1 (sl) 2017-03-31
AU2013253372B2 (en) 2016-12-08
IL235044A0 (en) 2014-12-31
US20170066752A1 (en) 2017-03-09
US20210115030A1 (en) 2021-04-22
DK2841431T3 (en) 2017-03-06
IN2014DN08867A (es) 2015-05-22
CO7111315A2 (es) 2014-11-10
WO2013162046A1 (en) 2013-10-31
DK2841431T4 (da) 2024-02-12
ES2617881T3 (es) 2017-06-20
AU2013253372A1 (en) 2014-10-30
US20150087655A1 (en) 2015-03-26
PH12014502324A1 (en) 2015-01-12
IL235044B (en) 2019-05-30
TW201348229A (zh) 2013-12-01
JP5952917B2 (ja) 2016-07-13
ZA201407477B (en) 2015-12-23
SMT201700130B (it) 2017-03-08
LT2841431T (lt) 2017-03-27
BR112014026424B1 (pt) 2022-09-13
EP2841431B2 (en) 2024-01-24

Similar Documents

Publication Publication Date Title
MX361723B (es) Dihidrato de un compuesto de benzotiofeno o de una sal del mismo y proceso para producir el mismo.
MX363127B (es) Derivados de benzotiofeno como inhibidores del receptor de estrogeno.
PH12015502658A1 (en) 3,4-dihydroisoquinolin-2 (1h)-yl compounds
MX347917B (es) Compuestos a base de imidazo[1,2-b]piridazina, composiciones que los comprenden, y metodos para su uso.
UA110354C2 (uk) Противірусні сполуки
PH12015500211A1 (en) 4-methyl-2,3,5,9,9b-pentaaza-cyclopenta[a]naphthalenes
MX2014002836A (es) Derivados de aminopirimidina para usarse como moduladores de la actividad de cinasa.
PH12014502513A1 (en) Nampt inhibitors
MX2014013752A (es) Inhibidores de nampt.
MX2013012652A (es) Derivados de n-[(1h-pirazol-1-il)aril]-1h-indol o 1h-indazol-3-carboxamida, su preparacion y su uso como antagonistas p2y12.
TN2015000120A1 (en) Oxazolidin-2-one-pyrimidine derivatives
PH12014501195A1 (en) Novel 2h-indazoles as ep2, receptor antagonists
SG10201900954SA (en) Heterocycles as Modulators of Kinase Activity
TN2014000532A1 (en) N-[4-(Quinolin-4-yloxy)cyclohexyl(methyl)](hetero)arylcarboxamides as androgen receptor antagonists, production and use thereof as medicinal products
MX2014007364A (es) Nuevas carboxamidas heterociclicas como modulares de la activadad de cinasas.
PH12015500322A1 (en) Tris(hetero)arylpyrazoles and use thereof
MX2015005312A (es) Derivados de 1h-indazol-3-carboxamida y uso de los mismos como antagonistas de p2y12.
IN2014DN10683A (es)
MX2013002446A (es) Derivados de tetrahidropirrolopirazina sustituidos.
GB2527958A (en) Pregnane-oximino-aminoalkylethers and process for preparation thereof, useful as antidiabetic and antidyslipidemic agents

Legal Events

Date Code Title Description
FG Grant or registration